Economy News Shares

Johnson & Johnson booster shot has been approved


The U.S. Food and Drug Administration’s (FDA) External Advisory Committee (EAC) has approved Johnson & Johnson (J&J) new Coronavirus vaccine (Covid-19) booster shot.

Providing there are no defects, J&J’s Covid-19 vaccine should be an effective booster shot, just like Pfizer’s vaccine.

Janssen vaccine booster shots will only be administered to adults 18 years of age and older.

As reported by foreign media outlets such as CNBC and the Wall Street Journal (WSJ), the FDA’s Vaccine and Related Biologics Advisory Committee (VRBPAC) unanimously recommended approval of the J&J vaccine booster shot.

Through its subsidiary Janssen, J&J produces more than 15 million vaccines in the US each year. As opposed to other vaccines available from Pfizer, Moderna, and AstraZeneca, the Janssen vaccine only requires one dose.

However, it showed less effectiveness than the Pfizer and Moderna vaccines. Both are messenger RNA (mRNA) vaccines, which require two doses.

If booster shots reinforce the effects of the vaccine, demand for the vaccine should also increase.

VRBPAC had recommended approval of Moderna booster shots despite a negative FDA review report the day before. It was a unanimous decision.

As for Moderna vaccines, the VRBPAC restricts the administration of booster shots to people 65 and older, immunocompromised individuals, and those employed in medical institutions. The same standards apply to Pfizer booster shots.

The J&J vaccine, which is a one-dose vaccine, has extended the target group for booster vaccination to those over the age of 18.

In the advisory committee report, the FDA recommended a booster shot within two months of the first dose. The recommendation targets anyone over 18 years of age who already received the Janssen vaccine.

Members of the advisory committee also considered that the Janssen booster shot could be similar to the second dose from Pfizer or Moderna.

A decision regarding booster shots of Moderna and Janssen vaccines is expected next week from the FDA.

For MetaNews.


Jonathan Hobbs

Jonathan Hobbs is an Australian investor and author that trades on a variety of asset classes, including currencies, equities, and commodities. Jonathan’s experience as a macro trader leverages his unique writing style to combine important elements, such as technical analysis and news. The other elements that he brings into his unique writing styles are foundation analysis aimed at rational equilibrium values, evaluating the sizes and motivations of buyers and sellers, as well as identifying the needs of the buyers and sellers in the individual markets. Jonathan is committed to quality writing for new traders as well as veterans.

Related Posts